sq-11725 has been researched along with Disease Models, Animal in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A; Tam, KY | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Gamelli, RL; Hasan, S; Mosier, MJ; Muthumalaiappan, K; Szilagyi, A | 1 |
| Bond, RA; Eikenburg, DC; Joshi, R; Kim, H; Knoll, BJ; Valdez, D | 1 |
| Dang, V; Das, D; Lin, B; Martin, KJ; Medina, B; Moghadam, S; Naik, P; Nosheny, R; Patel, D; Salehi, A; Wesson Ashford, J | 1 |
| Fujii, Y; Inagaki, T; Kuwahira, I; Nagai, H; Nara, A; Ogura, S; Pearson, JT; Schwenke, DO; Shimosawa, T; Shirai, M; Tsuchimochi, H; Uemura, K; Umetani, K; Yoshida, K | 1 |
| Campos-Rodríguez, R; Godínez-Victoria, M; Jarillo-Luna, RA; Miliar-García, A; Oros-Pantoja, R; Pacheco-Yépez, J; Rivera-Aguilar, V | 1 |
| Lipworth, BJ; Williamson, PA | 1 |
| Bundgaard, H; Chia, KK; Figtree, GA; Garcia, A; Hamilton, EJ; Huang, Y; Hunyor, SN; Liu, CC; Rasmussen, HH | 1 |
| Cohen, H; Geva, AB; Kaplan, Z; Koresh, O; Matar, MA; Zohar, J | 1 |
| Alfaro, VY; Bond, RA; Dickey, BF; Nguyen, LP; Okulate, AA; Singh, B; Tuvim, MJ | 1 |
| Camp, RM; Johnson, JD; Kalburgi, SN; Porterfield, VM; Remus, JL | 1 |
| Cain, DP; Saber, AJ | 1 |
| Ammar-Aouchiche, Z; Bond, RA; Clement, C; Dickey, BF; Ehre, C; Frieske, JM; Ho, SB; Kesimer, M; Knoll, BJ; Nguyen, LP; Omoluabi, O; Parra, S; Tuvim, MJ | 1 |
| Chupp, GL | 1 |
| Pruett, SB; Wu, WJ | 1 |
| Kalish, R; Kydonieus, A; Wille, JJ; Wood, JA | 1 |
| Fischbach, PS; Friedrichs, GS; Johnston, PV; Lucchesi, BR | 1 |
18 other study(ies) available for sq-11725 and Disease Models, Animal
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia.
Topics: Adrenergic Antagonists; Anemia; Animals; Burns; Butoxamine; Disease Models, Animal; Erythropoiesis; Male; Mice; Nadolol; Propanolamines; Propranolol; Receptors, Adrenergic, beta | 2017 |
Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.
Topics: Adrenergic beta-Antagonists; Animals; Asthma; Carbazoles; Carvedilol; Disease Models, Animal; Inflammation; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nadolol; Ovalbumin; Phenotype; Phosphorylation; Propanolamines; Pyroglyphidae; Respiratory Hypersensitivity | 2017 |
Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Cell Proliferation; Dendrites; Disease Models, Animal; Doublecortin Domain Proteins; Down Syndrome; Ethanolamines; Fibroblast Growth Factor 2; Formoterol Fumarate; Gene Expression Regulation; Hippocampus; Humans; Male; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Nadolol; Neurons; Neuropeptides; Receptors, Adrenergic, beta-2; Synaptophysin | 2014 |
β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
Topics: Adrenergic beta-2 Receptor Antagonists; Animals; Blood Pressure; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Disease Progression; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Nadolol; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Rats; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Time Factors; Vasoconstriction | 2014 |
Nasal IgA secretion in a murine model of acute stress. The possible role of catecholamines.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Catecholamines; Corticosterone; Cytokines; Disease Models, Animal; Immunoglobulin A; Immunoglobulin A, Secretory; Male; Mice; Mucous Membrane; Nadolol; Oxidopamine; Phentolamine; RNA, Messenger; Stress, Psychological; Sympathectomy, Chemical; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
Beta blockers for asthma: a double-edged sword.
Topics: Adrenergic beta-Antagonists; Animals; Asthma; Contraindications; Disease Models, Animal; Humans; Nadolol | 2009 |
β(3) adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Dioxoles; Disease Models, Animal; Ethanolamines; Glutathione; Heart Failure; Mice; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Nadolol; Oxidative Stress; Patch-Clamp Techniques; Rabbits; Receptors, Adrenergic, beta-3; Sheep; Sodium; Sodium-Potassium-Exchanging ATPase | 2010 |
Early post-stressor intervention with propranolol is ineffective in preventing posttraumatic stress responses in an animal model for PTSD.
Topics: Adrenergic beta-Antagonists; Animals; Anxiety; Behavior, Animal; Cues; Disease Models, Animal; Heart Rate; Injections, Subcutaneous; Male; Maze Learning; Memory; Memory, Long-Term; Nadolol; Propranolol; Rats; Rats, Sprague-Dawley; Reflex, Startle; Stress Disorders, Post-Traumatic; Stress, Psychological; Time Factors; Treatment Outcome | 2011 |
Complementary anti-inflammatory effects of a β-blocker and a corticosteroid in an asthma model.
Topics: Adrenergic beta-2 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Glucocorticoids; Leukocyte Count; Mice; Mice, Inbred BALB C; Mucins; Nadolol; Respiratory Mucosa | 2012 |
Fear conditioning can contribute to behavioral changes observed in a repeated stress model.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Conditioning, Psychological; Corticosterone; Disease Models, Animal; Environment; Exploratory Behavior; Fear; Food Preferences; Glucocorticoids; Interpersonal Relations; Nadolol; Propranolol; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Stress, Psychological; Sucrose | 2012 |
Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists.
Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Male; Maze Learning; Muscarinic Antagonists; Nadolol; Propranolol; Psychomotor Performance; Rats; Rats, Long-Evans; Scopolamine; Spatial Behavior; Time Factors | 2003 |
Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Asthma; Disease Models, Animal; Female; Inflammation; Infusion Pumps; Injections, Intraperitoneal; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mucins; Nadolol; Ovalbumin; Propanolamines; Specific Pathogen-Free Organisms | 2008 |
Say what, beta-blockers for asthma?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Infusion Pumps; Injections, Intraperitoneal; Mice; Mucins; Nadolol; Ovalbumin; Propanolamines; Reproducibility of Results | 2008 |
Suppression of splenic natural killer cell activity in a mouse model for binge drinking. II. Role of the neuroendocrine system.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alcoholism; Animals; Azides; Benzodiazepines; Carbolines; Catecholamines; Corticosterone; Diazepam; Disease Models, Animal; Female; GABA-A Receptor Agonists; Glucocorticoids; Immunity, Cellular; Immunity, Innate; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mifepristone; Nadolol; Naltrexone; Neurosecretory Systems; Oxidopamine; Phentolamine; Picrotoxin; Propranolol; Receptors, GABA-A; Spleen; Sympathetic Nervous System | 1996 |
Sensitization of mice to topically applied drugs: albuterol, chlorpheniramine, clonidine and nadolol.
Topics: Administration, Cutaneous; Albuterol; Animals; Anti-Asthmatic Agents; Antihypertensive Agents; Biological Availability; Chlorpheniramine; Clonidine; Dermatitis, Allergic Contact; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; Female; Histamine Agonists; Linear Models; Mice; Mice, Inbred CBA; Nadolol; Skin Absorption; Vitamin A | 1996 |
Tedisamil in a chronic canine model of atrial flutter.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Atrial Flutter; Bridged Bicyclo Compounds, Heterocyclic; Chronic Disease; Cyclopropanes; Disease Models, Animal; Dogs; Electrocardiography; Male; Nadolol; Potassium Channel Blockers | 1999 |